Royalty Report: Drugs, cell therapy, Cancer – Collection: 383557

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • cell therapy
  • Cancer
  • Stem cells
  • Biotechnology
  • Medical
  • bone marrow
  • Drug Discovery
  • Therapeutic
  • Pharmaceuticals
  • Supply
  • Disease
  • Test/Monitoring
  • Antibody
  • Specialty
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 383557

License Grant
Licensor grants the Licensee of Japan an exclusive license in the Territory, with the right to grant sublicenses, under the Licensor Patents and Licensor Technology to develop, register and to obtain Product Registrations, use, make, have made, import, export, offer to sell, sell and have sold Products for use in the Field in the Territory.
License Property
Licensor is the owner of certain technology, including, but not limited to patents and know-how, relating to mesenchymal stem cells.

MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.

Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.

The patents include
—  Monoclonal antibodies specific for marrow-derived mesenchymal cells;
—  Uses for non-autologus mesenchymal stem cells;
—  Osteoporosis bond regeneration;
—  Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
—  Mesenchymal stem cells as immunosuppressants;
—  Regulation of Hema topoietic stem cell  differentiation by the use of human mesenchymal stem cells;
—  Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.

Field of Use
The Field means the use of MSC in or in conjunction with the treatment of hematological malignancies by the use of hematopoietic stem cells derived from peripheral blood, cord blood or bone marrow.

Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 26091

License Grant
University grants Company a sole and exclusive worldwide License, under the Technology, Existing Patent Rights (to the extent not owned by the Company) and Developed Patent Rights  to make, have made, use and sell Product and Process,  including the right to grant sublicenses.
License Property
Existing Patent Rights shall mean (i) A Method for Isolating, Purifying and Culturally Expanding Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 615,430); (ii) Monoclonal Antibodies Specific for Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 716,917); (iii) A Method and Device for Enhancing the Implantation and Differentiation of Marrow-Derived Mesenchymal Cells (U.S. Patent Application No. 614,915); and (iv) A Method and Device for Treating Connective Tissue Disorders (U.S. Patent Application No. 614,912); any division, continuation, or continuation-in-part thereof and any foreign patent application or equivalent corresponding thereto and any Letters Patent or the equivalent thereof in any country of the world.

Developed Patent Rights shall mean any and all patents and patent applications anywhere in the world which contains one or more claims directed to Technology, which is not an Existing Patent Right.

Technology shall mean any and all existing or future information, technical data, inventions, discoveries or know-how, and materials whether or not patented or patentable, related to or useful for the  identification, isolation, purification, propagation or of use of mesenchymal stem cells and/or cells or products derived from or produced by mesenchymal stem cells, which are conceived, developed or reduced to practice by an Investigator while performing research at the University.

IPSCIO Record ID: 297144

License Grant
The Company acquired an exclusive license (and a right to sub-license) to the technology and know-how relating to an isolation and commercial scale expansion methodology of GMP grade human umbilical cord mesenchymal stem/stromal cells (“MSC”).
License Property
Mesenchymal stem cells (“HucMSC”) – a methodology for producing large numbers of clinical-grade pooled human umbilical cord.

Mesenchymal stem cells is for the medical research and biotech community that offers large volumes of high-quality, low passage human umbilical cord mesenchymal stem cells with minimal batch-to-batch variability.

Field of Use
This agreement pertains to the medical industry relating to stem cells.

IPSCIO Record ID: 26487

License Grant
The Licensor hereby grants to Switzerland company an exclusive (including as to Licensor and its Affiliates) royalty-bearing license to register, distribute, market, use and sell the Products in the Territory under the Licensor'd Patent Rights and the Licensor's Technology.
License Property
Products shall mean each article of manufacture, substance, material, chemical, formulation or composition which is or includes Thalidomide as an active ingredient, including, without limitation, any composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s).

The term Products expressly excludes Thalidomide analogs.  The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma.  Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 29036

License Grant
The Registrant sold its Eligix(TM) HDM Cell Separation System business to the German Buyer.
License Property
The Eligix(TM) HDM Cell Separation Systems use monoclonal antibodies to remove unwanted cells from bone marrow, peripheral blood stem cell and donor leukocyte grafts used in transplant procedures.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

IPSCIO Record ID: 360156

License Grant
Swss Licensor provided Licensee with a royalty-bearing license (with the right to grant sublicenses through multiple tiers) to utilize patents and know-how to conduct research and to develop, make, use or offer for sale products developed from certain single chain fragment variable compounds known as DLX105 and DLX2751 owned by the Licensor.
License Property
DLX105 and DLX2751 means antibody therapies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies.
Field of Use
Field of use is for the treatment for the treatment of solid and hematological malignancies.

Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. This classification includes various types of leukemia (acute lymphocytic (ALL), chronic lymphocytic (CLL), acute myeloid (AML), chronic myeloid (CML)), myeloma, and lymphoma (Hodgkin's and non-Hodgkin's (NHL)).

IPSCIO Record ID: 336338

License Grant
Licensor, a non-profit health care organization, grants to Licensee the worldwide and exclusive license with a right to sublicense, under the Patent Rights, to make, have made, use, have used, offer for sale, have offered for sale, import, have imported, have sold and sell the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field of Use to the end of the Term, unless sooner terminated as provided in this Agreement.
License Property
Rights relate to therapeutic compositions of modulated HSCs and methods for promoting reconstitution of the hematopoietic system using modulators of the prostaglandin pathway.

Licensor is the co-owner with a Hospital Corporation of certain Patent Rights.  The patents are Method to Modulate Hematopoietic Stem Cell Growth, and, Method to Enhance Tissue Regeneration.

ZON IND shall mean the investigational new drug application titled A Phase I Study of Reduced Intensity, Sequential Double Umbilical Cord Blood Transplantation Using Ex-Vivo 16,16 Dimethyl-Prostaglandin E2 Expanded Umbilical Cord Blood Units.

Field of Use
Licensee's HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, or HSCs, which are adult stem cells that regenerate all types of blood cells throughout a person’s lifespan. HSCs have been used for decades in a potentially curative procedure called hematopoietic stem cell transplant, or HSCT. This procedure is most commonly used in patients with hematologic malignancies to replace a diseased hematopoietic system with a healthy one. While over one million HSCT procedures have been performed to date, we believe HSCs have not been pharmacologically optimized to improve patient outcomes. Licensee'sHSC modulation platform has the potential to generate products that will improve patient outcomes in orphan indications by enhancing hematopoietic reconstitution through accelerated, durable engraftment, permitting greater donor matching flexibility, reducing the risk of major side effects and enabling the use of less toxic conditioning regimens.

Licensee's lead product candidate, ProHema, is a pharmacologically modulated HSC therapeutic derived from umbilical cord blood. Licensee has established human proof-of-concept for ProHema in the clinical setting by demonstrating enhanced and durable engraftment of HSCs within the bone marrow. Engraftment, which is the localization and integration of HSCs within a targeted tissue where they can produce new cells, is an important determinant of patient outcomes in HSCT. Licensee is presently advancing ProHema in Phase 2 clinical development for hematologic malignancies. Licensee is also pursuing the development of pharmacologically optimized HSC therapeutics for the treatment of certain lysosomal storage disorders, or LSDs, where HSCs have demonstrated the ability to home, or migrate, to and engraft within the central nervous system, or CNS.

IPSCIO Record ID: 335

License Grant
In this agreement the Company entered into a definitive license agreement and an exclusive option agreement to negotiate a commercial license. The Israeli Licensor, a shareholder of Licensee, is the technology transfer and commercial arm of an Institute of Science for research conducted for an invention comprising methods of bone marrow transplantation and cell therapy utilizing Veto cells.

The Licensor granted the Company an exclusive worldwide license under the licensed information and the patents for the development, manufacture and sale of the products.

License Property
The Licensor is involved with research for an invention comprising methods of bone marrow transplantation and cell therapy utilizing Veto-Cells. Veto-Cell immune system management technology, is an immune tolerance biotechnology that enables the selective blocking of immune responses.

Our Veto-Cell technology is a next generation cell-therapy technology that enables the selective attenuation of the immune system. In other words, pre-clinical studies suggest that the treatment has the ability to reduce the immune response to selective “threats,” with low risk for adverse side effects.

IPSCIO Record ID: 246210

License Grant
The Licensor grants the Licensee an exclusive licence to use, process, test and store the Materials (umbilical cord tissue samples) and Mesenchymal Stem Cells;  produce Licensed Product, including the creation of Derivatives and Progeny from Materials;  supply Licensed Product to third parties and to provide services in relation to such Licensed Product to third parties; and sub-licence its rights to Affiliates and to third party service providers.
License Property
The procurement of Mesenchymal Stem Cells derived from umbilical cord blood or placenta to be used for research purposes.  Materials are only for use in humans or for human application.
Field of Use
Cord Blood/Tissue, derived cells, progeny or derivative may be supplied and used in research projects if conducted in accordance with certain conditions.

License is for the methodology for producing clinical-grade pooled human umbilical cord derived mesenchymal stem/stromal cells (“HucMSC”) at industrial scale.

IPSCIO Record ID: 7534

License Grant
Israeli Licensor hereby grants to Israeli Licensee an exclusive, royalty-bearing, worldwide license under Licensor’s rights in the Licensed Technology to research, have researched, develop, have developed, manufacture, have manufactured, use, market, distribute, offer for sale, sell, have sold, export and import Licensed Products and/or provide services relating thereto.
License Property
“Drug” means 4F-benzoyl- TN14003.

BL-8040 (formerly BKT-140) is for the treatment of acute myeloid leukemia, as well as other types of hematological cancer (the “Drug”).

BL-8040, is a novel short peptide that functions as a high-affinity antagonist for CXCR4, which we intend to develop for AML, and other hematological indications. BL-8040 mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo- and bio-based anti-cancer therapy. In addition, BL-8040 has demonstrated a direct anti-cancer effect by inducing apoptosis (cell death). Multiple pre-clinical studies have shown the safety and efficacy of BL-8040. BL-8040 also mobilizes stem cells from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation in cancer patients.

Field of Use
BL-8040 is a novel peptide for the treatment of acute myeloid leukemia and other hematological indications.

IPSCIO Record ID: 3624

License Grant
The Israeli Licensor hereby grants to the Licensee, an exclusive license to exploit in any manner and for any and all purposes the Patent, including the right to grant sublicenses, make, have made, use, market and sell the Products.
License Property
The Company entered into a License Agreement to acquire a License of stem cell expansion technology related to bone marrow transplants. The Company received an exclusive, worldwide License to use the technology over the life of the related patent. The License grants exclusivity over all products, uses and related intellectual property, and grants the Company the right to enter into sub-Licenses. This technology, if fully developed, will offer novel solutions to make procedures like bone marrow transplants and other methods of cell therapy more accessible to patients suffering from leukemia, lymphoma, myeloma and a broad range of complicated diseases and disorders.

IPSCIO Record ID: 26064

License Grant
Licensor, Chief Scientific Officer of Licensee, hereby grants to Licensee and its Affiliates during the Term an exclusive, worldwide, royalty bearing license, with the right to grant sublicenses through multiple tiers of sublicenses, in and to, the Technology, Licensed Products, Licensed Improvements, and Patents; and to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products.
Sublicenses – In the event that Licensee sublicenses any of its rights hereunder to a Sublicense, such sublicense shall include terms and conditions consistent with the terms and conditions of the license granted under this Agreement Sublicenses, if any, granted hereunder, will be to Third Parties in an arm's length transaction under written agreements, copies of which will be provided to Licensor.
License Property
Licensed Technology – Ex Vivo Expansion of Cord Blood Cells Work has demonstrated that cells present in the CB mononuclear (MNC) fraction inhibit ex vivo expansion of the CD34+ cells. This inhibition can be overcome by co-culture on mesenchymal stem cells (MSC) and clinical studies are being undertaken to evaluate the potential of CB MNC cultured on MSC for 2 weeks.
The Company has evaluated the effects of removal of various mature cells by immvno selection and the depleted cells failed to expand. More recently we have evaluated the removal of red blood cells and have positive data for optimal removal of red cells and preliminary evidence that the red cell depleted products may expand up to 500 fold. This approach has a number of advantages including the passive removal of inhibitory cells which has minimal effect on total CD34+ cells. Future studies are required to generate data on the expansion potential of the depleted CB products, and this work will include proof of principle expo performed with frozen CB products to mimic the clinical setting.
The red cell depletion results in recovery of approx. 50 million white cells which would only be a cell dose 0.1 x 107 TNCI & With an expansion of only 100 fold this would result in a cell dose of 10.0 x 10' ThC/kg. Therefore an expansion of 500 fold would be sufficient for all adult patients to achieve a cell dose in the range of 10.0 x 107 TNC/kg, therefore making CB transplantation available to potential patients. In comparison, CD34 selection for expansion results in approx. 5 million cells post selection and would require an expansion of 1,000 fold or more to achieve similar cell doses. No studies have reported these levels of expansion consistently.
Field of Use
Licensee is engaged in research and development of stem cells, cord blood banking and expansion laboratory services and interested in developing and commercializing the Technology.

IPSCIO Record ID: 274909

License Grant
Licensor grants to the Licensee of the United Kingdom, and its Affiliates, an exclusive license under Licensor Background Patent Rights, Licensor Future Patent Rights, Licensor Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights, and Licensor Know-How to develop, have developed, make, have made, use, sell, have sold, and import Cellular Assay Products throughout the Territory in the Cellular Assay Products Field.

Licensor grants
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights and Licensor’s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.

Licensor grants an option to negotiate in good faith and on commercially reasonable terms
—  an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensor’s interest in Joint Alliance IP Rights, and;
—  a sub-license for the Cellular Assay Products Field in the Territory.

License Property
The patents and know-how are for certain intellectual property rights related to the propagation and differentiation of human embryonic derived cells.
Field of Use
The Cellular Assay Products Field shall mean the use of Cellular Assay Products for in vitro assay applications, including but not limited to drug discovery and development, drug monitoring, drug toxicology testing, and consumer products testing, but excluding the use of any Cellular Assay Product in any therapeutic or diagnostic application.

The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.

The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.

Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.

IPSCIO Record ID: 213098

License Grant
The Israeli Licensee signed an agreement with the Israeli Licensor to conduct a Phase I/II trial of PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-Versus-Host-Disease ('GvHD').
License Property
PLX-PAD – PLacental eXpanded cells are placenta-derived cells that are designed to be administered to patients without the need for tissue or genetic matching.
Field of Use
The Licensee is a developer of placenta-based cell therapy products.

Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person. GvHD is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. Immune cells (white blood cells) in the donated tissue (the graft) recognize the recipient (the host) as foreign (nonself).

IPSCIO Record ID: 330905

License Grant
Licensor, an affiliate of Licensee Chief Science Officer,  hereby grants to Licensee an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights and Technology to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process claimed in the Patent Rights.
License Property
U.S. Patent Application #13/819,154 – Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Technology known as
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair
Bone Marrow Derived CD271 Precursor Cells For Cardiac Repair

Field of Use
CD271+ technology is a subpopulation of bone marrow-derived MSCs.

Field of Use shall mean any aging related diseases or indications including frailty, metabolic syndrome, loss of muscle due to aging or frailty, and neurocognitive disorders.

IPSCIO Record ID: 245925

License Grant
Licensor hereby grants Licensee a nonexclusive license under the Licensed Patent Rights and the Licensed Technology to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory. The license shall include, without limitation, the right to (i) sell Products to purchasers and/or distributors in the Field and in the Territory and/or (ii) to collaborate with preclinical or clinical investigators in the Field and in the Territory provided such investigators are bound by the confidentiality provisions contained herein, and/or (iii) to sublicense to Affiliates of Licensee, to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory, provided that such Affiliates will be bound by the terms and conditions contained herein and/or (iv) to sublicense to Third Parties to develop, make, have made, and use Licensed Compounds ex vivo in the Territory for the purpose of developing, making, having made, using, having used, selling, having sold, offering for sale, importing, exporting and otherwise exploiting Products in the Field and in the Territory for use in combination with Licenseel Technology, provided such Third Party sublicensee shall be identified to Licensor and be bound by the applicable terms and conditions as contained herein.
License Property
Licensed Patent Rights shall be as defined
5,869,451 – Peptides and compounds that bind to a receptor
6,121,238 – Peptides and compounds that bind to a receptor
6,251,864 – Peptides and compounds that bind to a receptor
6,083,913 – Peptides and compounds that bind to a thrombopoietin receptor
5,932,546 – Peptides and compounds that bind to the thrombopoietin receptor

Licensed Technology shall mean the technology, know-how, data, information and results relating to the synthesis and characterization of Licensed Compound to be supplied to Licenseel, as referred to Pre-Clinical Evaluation of Tpo Mimetic Peptides Index to Analysis, Biology, Formulation, Pharmacology, Synthesis and DMPK.

Licensed Compound shall mean any composition of matter which uses and/or comprises the AF13948, AF15705, GW350805 and/or GW395058 compounds.

Product shall mean any cellular therapy or gene therapy product developed or manufactured using a Licensed Compound, for which the use of the Licensed Compound would, but for the license granted hereunder, otherwise infringe a Valid Claim of the Licensed Patent Rights.

Thrombopoietin mimetics are drugs that considerably increase platelet production by stimulating the receptor for the hormone thrombopoietin.

Field of Use
Field shall mean ex vivo cell therapy and ex vivo gene therapy. The Field excludes parenteral or in vivo therapies, which are expressly reserved for Licensor or such third parties to whom such uses may be licensed by Licensor, provided that the Field shall include ex vivo and extra-corporeal uses where the primary intended activity of the Licensed Compound is ex vivo and any residuals thereof which may be introduced in vivo have no significant medical or therapeutic benefit. 'Extra-corporeal' means a process where a patients cells are extracted, processed and infused back into a subject by a device while the subject remains connected to the device.

The forms of TPO-mimetic is for use as a reagent in producing stem cell therapy products, including CB001.

CB001 is manufactured using one of Licensee's proprietary technologies which allows the isolation, purification and significant expansion of populations of stem cells. Licensee believe this proprietary technology will enable the production of well defined cellular products in therapeutically useful quantities. We are developing CB001 for use in bone marrow and other hematopoietic stem cell transplants.  CB001 has entered a Phase I/II clinical trial in older adolescents and adults.

IPSCIO Record ID: 280934

License Grant
This agreement is for development and commercialization of the clinical compound forodesine hydrochloride in markets across Europe, Asia and Australasia.

Licensor grants the Licensee of Bermuda an exclusive right and license in the Territory, with the right to sublicense, to Develop, make, have made, package and have packaged, use, promote, market, offer for sale, sell and import Licensed Products in the Field, under the Licensor Patents, Licensor Know-How and the Trademark.

Licensor grants during the Term of this Agreement a limited non-exclusive right to use the Licensor Logo on Promotional Literature in the Field in the Territory.

License Property
Licensor owns or controls patents and know-how related to a series of proprietary compounds which act as PNP Inhibitors, including the compound known as __X-1777.

Licensed Products means all pharmaceutical preparations in all dosage strengths, formulations and methods of administration that contain the Compound as its active ingredient, alone or in combination with another active ingredient.

Trademark means the trademark Fodosine or such other trademark approved by the JDC for use in connection with the Licensed Products, but excluding the Secondary Marks.

B-cell Acute Lymphoblastic Leukemia/lymphoma or B-ALL means a disease in which certain cells of the B lymphocytes or B-cells are malignant, and have populated the bone marrow.

B-CLL means B-type chronic lymphocytic leukemia.

B-NHL means a Non-Hodgkin’s lymphoma in which the malignant cells have characteristics predominantly of the B lineage.

Field of Use
Field means the treatment of all Cancerous and/or Pre-Cancerous States in humans, specifically for the treatment of certain T-cell and B-cell mediated diseases in the area of oncology.
Fodosineâ„¢ is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP). The drug is currently being studied in a number of clinical trials including a Phase IIa clinical trial in patients with T-cell leukemia.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.